Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $52.83 and last traded at $52.83, with a volume of 0 shares. The stock had previously closed at $52.83.
Analyst Upgrades and Downgrades
Separately, HC Wainwright upgraded shares of Basilea Pharmaceutica to a “strong-buy” rating in a research report on Monday, September 23rd.
Read Our Latest Stock Analysis on BPMUF
Basilea Pharmaceutica Price Performance
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
See Also
- Five stocks we like better than Basilea Pharmaceutica
- How to Buy Cheap Stocks Step by Step
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Golden Cross Stocks: Pattern, Examples and Charts
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- The Most Important Warren Buffett Stock for Investors: His Own
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
